Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
29,318,781
-
Share change
-
+2,667,763
-
Total reported value
-
$476,437,910
-
Put/Call ratio
-
59%
-
Price per share
-
$16.25
-
Number of holders
-
113
-
Value change
-
+$46,854,550
-
Number of buys
-
46
-
Number of sells
-
59
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q1 2017
As of 31 Mar 2017,
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) was held by
113 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,318,781 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., VANGUARD GROUP INC, BB BIOTECH AG, WASATCH ADVISORS INC, Hillhouse Capital Management, Ltd., STATE STREET CORP, Clough Capital Partners L P, CITADEL ADVISORS LLC, and Rhenman & Partners Asset Management AB.
This page lists
113
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.